Qiagen (NYSE:QGEN) Releases Q1 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its first quarter 2025 earnings guidance on Monday. The company provided earnings per share guidance of 0.550- for the period, compared to the consensus earnings per share estimate of 0.490. The company issued revenue guidance of $483.0 million-, compared to the consensus revenue estimate of $464.8 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on QGEN shares. Morgan Stanley reissued an “equal weight” rating and set a $46.67 price target (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Robert W. Baird lowered Qiagen from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $52.00 to $42.00 in a research report on Wednesday, February 19th. UBS Group reduced their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Finally, Redburn Atlantic lowered Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $47.71.

Qiagen Stock Performance

Shares of NYSE:QGEN opened at $38.24 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The firm has a market cap of $8.50 billion, a PE ratio of 106.48, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. The firm’s 50 day simple moving average is $40.27 and its 200-day simple moving average is $41.94. Qiagen has a one year low of $37.63 and a one year high of $49.30.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. As a group, equities analysts predict that Qiagen will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.